The Readout Loud 352: A firebrand takes oversight of vaccines, gene therapies
8 snips
May 8, 2025 
Matt Herper, STAT's senior medicine writer with a knack for dissecting the pharmaceutical industry, joins the conversation to discuss the controversial appointment of Dr. Vinay Prasad as head of the FDA's vaccine division. He and Adam delve into how Prasad's unorthodox views could disrupt public health norms. They also explore the implications for gene and cell therapy approvals and the broader challenges facing biotech innovation under new leadership. The dialogue highlights the tension between regulatory reform and maintaining expert oversight in a rapidly evolving landscape.
AI Snips
Chapters
Transcript
Episode notes
Prasad's Controversial Appointment
- Vinay Prasad is a controversial figure known for sharply criticizing drug trials and FDA policies.
- His appointment to run CBER surprised many due to his dramatic criticisms of the agency.
Prasad's Abrasive Style and COVID Impact
- Prasad's critique style is abrasive, which has alienated many but also built a large following.
- COVID-era views intensified his rhetoric, linking him to former Trump administration health officials.
Oncologist's Mixed Feelings on Prasad
- An oncologist admires Prasad's ideas but finds his delivery so abrasive it elicits strong negative emotions.
- This illustrates the polarizing effect of Prasad's communication style among medical professionals.